[Construction of VEGF eukaryotic expression vector and its expression in endothelial cells and cardiac myocytes in-vitro].
To study the feasibility of VEGF165 gene transfection to endothelial cells and cardiac myocytes in-vitro. The VEGF165 DNA fragment was inserted into a green fluorescent protein fusion vector, which was then transfected into endothelial cells and cardiac myocytes with lipofectamine. The endothelial cells and cardiac myocytes were successfully transfected with pIRES2-EGFP-hVEGF165 gene, which was confirmed by fluoroscopy and immunohistochemistry. VEGF can be expressed stably in the endothelial cells and cardiac myocytes, which might be useful for the gene therapy of myocardial ischemia.